Malignancies developing in obese patients with psoriasis while on antitumour necrosis factor-α therapies: a case series

2012 ◽  
Vol 167 (4) ◽  
pp. 937-938 ◽  
Author(s):  
M. Sadlier ◽  
A. Lally ◽  
B. Kirby
Keyword(s):  
Case Series ◽  
Obese Patients ◽  
Factor Α ◽  
Necrosis Factor

Safety and Efficacy of Adalimumab for the Treatment of Severe Alopecia Areata: Case Series of Three Patients

2012 ◽  
Vol 16 (4) ◽  
pp. 257-260 ◽  
Author(s):  
Chantal Bolduc ◽  
Robert Bissonnette
Keyword(s):  
Alopecia Areata ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Case Series ◽  
Efficacy And Safety ◽  
Open Label ◽  
Monthly Basis ◽  
Clinically Significant ◽  
Factor Α ◽  
Necrosis Factor

Background: Current therapeutic options for extensive alopecia areata (AA) often lead to disappointing results. Objective: To study the efficacy and safety of adalimumab in patients with severe AA. Methods: This was a prospective, open-label, single-center, pilot study. Three subjects of the planned 10 were enrolled and received two weekly subcutaneous (SC) loading doses of adalimumab 80 mg followed by 40 mg SC every week for 6 months. Patients were evaluated for efficacy and safety on a monthly basis. Results: Enrolment in this trial was stopped following publication of studies showing no improvement in patients with AA treated with tumor necrosis factor α antagonists. One patient had a favorable response to adalimumab, whereas the two other patients had no benefit from the therapy. Adalimumab was well tolerated by patients with AA. Conclusion: Adalimumab was well tolerated in patients with AA but did not induce clinically significant hair regrowth.

Infliximab Treatment of Sarcoidosis

2003 ◽  
Vol 37 (4) ◽  
pp. 577-581 ◽  
Author(s):  
Ryan N Serio
Keyword(s):  
Potential Role ◽  
Treatment Options ◽  
Case Series ◽  
Sufficient Evidence ◽  
Infliximab Treatment ◽  
Data Synthesis ◽  
First Line Therapy ◽  
Factor Α ◽  
Necrosis Factor ◽  
Treatment Of Sarcoidosis

OBJECTIVE: To determine whether there is sufficient evidence in the literature to support the use of infliximab in the treatment of sarcoidosis. DATA SOURCES AND SELECTION: Literature was accessed through MEDLINE (1966–August 2002), OVID (2001–January 2003), and bibliographic searches. Additional databases were also searched. Published literature relevant to the use of infliximab in the treatment of sarcoidosis was evaluated. DATA SYNTHESIS: In theory, tumor-necrosis factor-α blockade appears to be an optimal strategy for treating sarcoidosis. Case series reporting the use of infliximab in refractory sarcoidosis was reviewed to evaluate its potential role as a treatment option. CONCLUSIONS: Although there is insufficient evidence suggesting that infliximab is an appropriate alternative to conventional treatment options as first-line therapy for sarcoidosis, the preliminary outlook on its use in treatment-refractory cases is promising.

scholarly journals Serum Levels of Tumor Necrosis Factor-α Are Increased in Obese Patients with Noninsulin-Dependent Diabetes Mellitus1

1998 ◽  
Vol 83 (3) ◽  
pp. 859-862 ◽  
Author(s):  
Akira Katsuki ◽  
Yasuhiro Sumida ◽  
Shuichi Murashima ◽  
Kazuya Murata ◽  
Yoshihiro Takarada ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Serum Levels ◽  
Obese Patients ◽  
Factor Α ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document